Literature DB >> 22986743

Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.

Hong Sug Kim1, Kevin Woolard, Chen Lai, Peter O Bauer, Dragan Maric, Hua Song, Aiguo Li, Svetlana Kotliarova, Wei Zhang, Howard A Fine.   

Abstract

Glioblastoma multiforme is the most common type of primary malignant brain tumor and may arise from a cell with neural stem-like properties. Deregulation of the retinoblastoma, phosphoinositide-3 kinase (PI3K), and p53 pathways are molecular hallmarks of this disease. Recent work has shown that p53(-/-)Pten(-/-) mice form gliomas in a c-Myc-dependent manner. To explore the role of the INK4A/ARF locus and Pten deletions in gliomagenesis, we generated Pten(-/-)Ink4a/Arf(-/-) mouse neural stem cells (mNSC) and such cells were highly proliferative, self-renewing, relatively refractory to differentiation, and induced both low- and high-grade glioma formation in vivo. In contrast to p53(-/-) Pten(-/-) mNSCs, however, Pten(-/-)Ink4a/Arf(-/-) mNSCs do not express appreciable levels of c-Myc in vitro, although glioma stem cells derived from thesecells did. Sequencing of Pten(-/-)Ink4a/Arf(-/-) mNSC-derived tumors revealed spontaneous mutations in Tp53 in vivo with subsequent downregulation of Fbxw7. Expression of p53 mutants in Pten(-/-)Ink4a/Arf(-/-) mNSC or knockdown of Fbxw7 resulted in reexpression of c-Myc with enhanced Pten(-/-)Ink4a/Arf(-/-) mNSC tumorigenecity. We propose that p53 mutations contribute to gliomagenesis by both allowing the overexpression of c-Myc through downregulation of Fbxw7 and by protecting against c-Myc-induced apoptosis. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22986743     DOI: 10.1158/0008-5472.CAN-12-2594

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Evolutionary etiology of high-grade astrocytomas.

Authors:  Yurong Song; Qian Zhang; Burak Kutlu; Simone Difilippantonio; Ryan Bash; Debra Gilbert; Chaoying Yin; T Norene O'Sullivan; Chunyu Yang; Serguei Kozlov; Elizabeth Bullitt; Ken D McCarthy; Tal Kafri; David N Louis; C Ryan Miller; Leroy Hood; Terry Van Dyke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-10       Impact factor: 11.205

2.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.

Authors:  Robert S McNeill; Ralf S Schmid; Ryan E Bash; Mark Vitucci; Kristen K White; Andrea M Werneke; Brian H Constance; Byron Huff; C Ryan Miller
Journal:  J Vis Exp       Date:  2014-08-12       Impact factor: 1.355

Review 3.  Ubiquitin ligases: guardians of mammalian development.

Authors:  David A Cruz Walma; Zhuoyao Chen; Alex N Bullock; Kenneth M Yamada
Journal:  Nat Rev Mol Cell Biol       Date:  2022-01-25       Impact factor: 113.915

4.  SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner.

Authors:  Ji-Seon Lee; Jeong-Rak Park; Ok-Seon Kwon; Tae-Hee Lee; Ichiro Nakano; Hiroyuki Miyoshi; Kwang-Hoon Chun; Myung-Jin Park; Hong Jun Lee; Seung U Kim; Hyuk-Jin Cha
Journal:  Neuro Oncol       Date:  2014-08-05       Impact factor: 12.300

5.  Integrated genomic characterization of IDH1-mutant glioma malignant progression.

Authors:  Hanwen Bai; Akdes Serin Harmancı; E Zeynep Erson-Omay; Jie Li; Süleyman Coşkun; Matthias Simon; Boris Krischek; Koray Özduman; S Bülent Omay; Eric A Sorensen; Şevin Turcan; Mehmet Bakırcığlu; Geneive Carrión-Grant; Phillip B Murray; Victoria E Clark; A Gulhan Ercan-Sencicek; James Knight; Leman Sencar; Selin Altınok; Leon D Kaulen; Burcu Gülez; Marco Timmer; Johannes Schramm; Ketu Mishra-Gorur; Octavian Henegariu; Jennifer Moliterno; Angeliki Louvi; Timothy A Chan; Stacey L Tannheimer; M Necmettin Pamir; Alexander O Vortmeyer; Kaya Bilguvar; Katsuhito Yasuno; Murat Günel
Journal:  Nat Genet       Date:  2015-11-30       Impact factor: 38.330

6.  Inhibition of BET bromodomain targets genetically diverse glioblastoma.

Authors:  Zhixiang Cheng; Yuanying Gong; Yufang Ma; Kaihua Lu; Xiang Lu; Larry A Pierce; Reid C Thompson; Susanne Muller; Stefan Knapp; Jialiang Wang
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

Review 7.  Contemporary murine models in preclinical astrocytoma drug development.

Authors:  Robert S McNeill; Mark Vitucci; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

8.  Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.

Authors:  Xianglan Yi; Liping Lou; Jun Wang; Jing Xiong; Sheng Zhou
Journal:  Cancer Chemother Pharmacol       Date:  2021-02-05       Impact factor: 3.333

9.  Micro-environment causes reversible changes in DNA methylation and mRNA expression profiles in patient-derived glioma stem cells.

Authors:  Mehmet Baysan; Kevin Woolard; Serdar Bozdag; Gregory Riddick; Svetlana Kotliarova; Margaret C Cam; Galina I Belova; Susie Ahn; Wei Zhang; Hua Song; Jennifer Walling; Holly Stevenson; Paul Meltzer; Howard A Fine
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

10.  Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.

Authors:  Jianxin Wang; Tianxiao Li; Bin Wang
Journal:  Int J Oncol       Date:  2021-07-19       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.